Copyright ©The Author(s) 2017.
World J Gastroenterol. Sep 7, 2017; 23(33): 6030-6048
Published online Sep 7, 2017. doi: 10.3748/wjg.v23.i33.6030
Table 4 Published data on autoimmune hepatitis treatment different from steroids and azathioprine in children
Ref.CountryNumber and type of patients (n)DesignOutcomeFollow-upDoseSide effects
Woynarowski et al[91], 2013Europe46 including naïve and second-lineProspective16% BR AZA+BUD 15% BR AZA+PDN at 6 mo1 yr6-9 mg/dMore weight gain in PDN group
Mycophenolate mofetil
Lee et al[107], 2007Malaysia2 second-lineRetrospective0/2 BR at 6 mo6-18 mo20-40 mg/kg/dNot reported
Aw et al[106], 2009United Kingdom20 AZA-NR 6 AZA-INTRetrospective18/26 CBR0.75-12 mo20-40 mg/kg/d7 Leukopaenia
Jiménenz-Rivera et al[108], 2012Canada12 second-lineRetrospectiveNot reportedNot reported1000-1500 mg/dNot reported
Dehghani et al[109], 2013Iran5 second-lineRetrospective5/5 BRNone reportedNot reportedNot reported
Cyclosporine A
Jackson et al[120], 1995South Africa1 AZA-INTRetrospective1/1 BR at 2 wk19 mo5 mg/kg/dNone
Debray et al[111], 1999France8 naïve 7 second-line (all type 2 AIH)Retrospective8/8 naïve BR 7/7 second-line (including 3 with ALF)1-6 yr4.7-5.6 mg/kg/dMinimal
Ben Halima etal[122], 2002Tunisia1 first-lineRetrospective1/1 BRNot reportedNot reportedNone
Sciveres et al[184], 2004Italy4 naïve 4 steroid/AZA-intolerantRetrospective8/8 BR at 2-8 wk1.5-15 yr4-10 mg/kg per day2 gingival hypertrophy, 1 creatinine elevation
Cuarterolo et al[124], 2006Agentina86 naïve, type 1 AIHProspectiveBR 94%2 yr4 mg/kg per day8/84 creatinine elevation 3/84 hypertension
Nastasio et al[115], 2011Italy19 naïve1 10 second-line1Retrospective19/19 naïve BR at 4-18 wk 9/10 second-line BR6.5 yrNot reported11 hyperthricosis, 13 gingival hypertrophy
Dehghani et al[109], 2013Iran3 second-lineRetrospective3/3 BRNot reportedNot reportedNot reported
Lee et al[107], 2015Malaysia2 second-lineRetrospective1 /2 BR6-18 mo5 mg/kg per day, serum level 250-350 ng/mL
Zaya et al[112], 2012Croatia9 naïve (1 type 2 AIH)Retrospective7/9 BR after 1 yr24 mo3-5 mg/kg per dayMinor
Jiménez-Rivera et al[108], 2012Canada9 naïve 15 second-lineRetrospectiveNot reported4 ± 2 yr4 ± 0.8 mg/kg per day intially 4.9 ± 1.8 mg/kg per day in follow-upNot reported
Zolfino et al[93], 2002United Kingdom1 second-lineRetrospectiveNRNot reported2 mg/dNot reported
Marlaka et al[138], 2012Sweden20 naïveProspective3/20 BR in monotherapy1 yrTarget blood levels: 2.5-5 ng/ml1 discontinued for side-effects; 2 developed IBD
Dehghani et al[109], 2013Iran2 second-lineRetrospective2/2 BRNot reportedNot reportedNot reported
Jiménez-Rivera et al[108], 2015Canada6 second-lineRetrospectiveNot reportedNot reportedNot reportedNot reported
Kurowski et al[140], 2014United States4 second-lineRetrospective2/4 BRNot reportedNot reported2 mo ulcers
D’Agostino et al[150], 2013Canada/Argentina2 second-lineRetrospective2/2 CBR at 3/8 mo26-38 mo375 mg/m2 weekly for 4 wkNone reported
Rajanayagam et al[158], 2013Australia1 second-lineRetrospective1/1 BR19 mo5 mg/kg 4 infusions at 4 wk intervalLT was not prevented
Pratt et al[167], 1996United States1 AZA-NRRetrospective1/1 CBR and HR36 mo1.5 mg/kgNone reported